Anna Theresa Santiago
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna Theresa Santiago has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
- David Benjamin Shultz
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
3 shared publications - Alejandro Berlin
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
2 shared publications Andrea Moser
Department of Family and Community Medicine, Baycrest, Toronto, ON, Canada
2 shared publicationsAnna Berall
Rotman Research Institute, Baycrest Health Sciences, Toronto, ON, Canada
2 shared publicationsCalen Freeman
2 shared publications- Cindy J. Grief
Baycrest
2 shared publications
Latest Publications
- Open Access
- 16 August 2026
- Published by Elsevier in SSRN Electronic Journal
Quality of Life Outcomes in Children Undergoing Reirradiation for Recurrent Brain Tumors: A Prospective Study
Purpose: Re-irradiation (re-RT) is increasingly used for children with recurrent or progressive brain tumours, including high-grade gliomas (HGG), yet its impact on health-related quality of life (HRQOL) remains poorly understood. Given the limited survival following relapse, maintaining HRQOL is a key treatment goal. We conducted a Canada-wide multi-centre prospective study to characterize HRQOL trajectories in children undergoing re-RT for recurrent brain tumours and their caregivers over time. Methods: Patients, under the age of 18 who underwent re-RT for brain tumours, and their caregivers, who provided informed consent, completed a set of validated questionnaires including the Pediatric Quality of Life Inventory (Acute Version; PedsQL) at the time of re-RT (baseline) and every two months for a total of 18 months. Changes in PedsQL scores post-re-RT were evaluated using linear mixed-effects models. This study was registered with ClinicalTrials.gov (Anonymized for Review). Results: Nineteen patients (40% male; median age 7.8 years old (range, 5-16 years) and their caregivers were enrolled between March 2020 and November 2024. Eleven patient-caregiver dyads had adequate HRQOL data at baseline and were included in the statistical analysis. Most patients had HGG (75%), including diffuse intrinsic pontine glioma. The median self-reported PedsQL Total Scale Score was 37.0 out of 100 (range, 19.6-58.7) at baseline (n=11), and 51.6 out of 100 (range, 8.7-92.4) 2 months post-re-RT (n=6). The median parent-proxy PedsQL Total Scale Score was 35.1 out of 100 (range, 23.0-41.4) at baseline (n=10), and 37 out of 100 (range, 13-94.6) 2 months post-re-RT (n=6). No significant change in overall HRQOL was observed for patient self-report or caregiver proxy-report at 2 months, among patients with available follow-up data. PedsQL physical health scores also remained stable over time. Among patients with HGG, psychosocial health scores demonstrated a significant decline at 2 months post-re-RT, while total and physical HRQOL scores remained unchanged. Longitudinal analyses demonstrated substantial inter-patient variability in HRQOL trajectories over time. Conclusions: Overall HRQOL and physical functioning were maintained following re-RT for recurrent or progressive pediatric brain tumours. Although psychosocial health declined among patients with HGG, no significant deterioration in overall HRQOL was observed, supporting re-RT as a feasible treatment option. Larger studies are needed to confirm these findings.
- 16 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessQuality of Life Outcomes in Children Undergoing Reirradiation for Recurrent Brain Tumors: A Prospective Study
Purpose: Re-irradiation (re-RT) is increasingly used for children with recurrent or progressive brain tumours, including high-grade gliomas (HGG), yet its impact on health-related quality of life (HRQOL) remains poorly understood. Given the limited survival following relapse, maintaining HRQOL is a key treatment goal. We conducted a Canada-wide multi-centre prospective study to characterize HRQOL trajectories in children undergoing re-RT for recurrent brain tumours and their caregivers over time. Methods: Patients, under the age of 18 who underwent re-RT for brain tumours, and their caregivers, who provided informed consent, completed a set of validated questionnaires including the Pediatric Quality of Life Inventory (Acute Version; PedsQL) at the time of re-RT (baseline) and every two months for a total of 18 months. Changes in PedsQL scores post-re-RT were evaluated using linear mixed-effects models. This study was registered with ClinicalTrials.gov (Anonymized for Review). Results: Nineteen patients (40% male; median age 7.8 years old (range, 5-16 years) and their caregivers were enrolled between March 2020 and November 2024. Eleven patient-caregiver dyads had adequate HRQOL data at baseline and were included in the statistical analysis. Most patients had HGG (75%), including diffuse intrinsic pontine glioma. The median self-reported PedsQL Total Scale Score was 37.0 out of 100 (range, 19.6-58.7) at baseline (n=11), and 51.6 out of 100 (range, 8.7-92.4) 2 months post-re-RT (n=6). The median parent-proxy PedsQL Total Scale Score was 35.1 out of 100 (range, 23.0-41.4) at baseline (n=10), and 37 out of 100 (range, 13-94.6) 2 months post-re-RT (n=6). No significant change in overall HRQOL was observed for patient self-report or caregiver proxy-report at 2 months, among patients with available follow-up data. PedsQL physical health scores also remained stable over time. Among patients with HGG, psychosocial health scores demonstrated a significant decline at 2 months post-re-RT, while total and physical HRQOL scores remained unchanged. Longitudinal analyses demonstrated substantial inter-patient variability in HRQOL trajectories over time. Conclusions: Overall HRQOL and physical functioning were maintained following re-RT for recurrent or progressive pediatric brain tumours. Although psychosocial health declined among patients with HGG, no significant deterioration in overall HRQOL was observed, supporting re-RT as a feasible treatment option. Larger studies are needed to confirm these findings.
- Open Access
- 3 July 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (7) , 398
Transition from Oncologist- to Therapist-Led MRI-Guided Ultra-Hypofractionated Adaptive Prostate Radiation Therapy: Evaluation of Early Clinical Outcomes
MR-guided adaptive radiotherapy (ART) enables daily plan optimization for prostate cancer but is resource-intensive. This study evaluated dosimetric and clinical outcomes following transition from radiation oncologist (RO)-led to radiation therapist (RTT)-led MR-guided ART. All prostate cancer patients treated with MR-guided ART on a 1.5T MR-linac were retrospectively reviewed. Consecutive RO-led (September 2019–November 2021) and RTT-led (April 2022–October 2023) cohorts were compared, excluding the actual transition period. Toxicities (CTCAE v5.0), dose–volume metrics from daily adapted plans, target volume variation, and biochemical recurrence-free survival (BRFS) were analyzed. A total of 166 patients were included (78 RO-led, 88 RTT-led; median follow-up 40 and 35 months). Dosimetric differences between the cohorts were statistically small (n = 2 vs. n = 0), likely reflecting higher baseline urinary dysfunction; no post-treatment differences persisted. Early biochemical outcomes were comparable, with 36-month BRFS of 93.5% (RO-led) and 95.0% (RTT-led). RTT-led MR-guided ART achieved comparable dosimetric quality and early biochemical outcomes to RO-led workflows with adverse advents that resolved in the long term. With structured training and a mature practice setting, RTT-led ART represents a scalable model to support future adaptive radiotherapy practice.
- 3 July 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (7) , 398
Open AccessTransition from Oncologist- to Therapist-Led MRI-Guided Ultra-Hypofractionated Adaptive Prostate Radiation Therapy: Evaluation of Early Clinical Outcomes
MR-guided adaptive radiotherapy (ART) enables daily plan optimization for prostate cancer but is resource-intensive. This study evaluated dosimetric and clinical outcomes following transition from radiation oncologist (RO)-led to radiation therapist (RTT)-led MR-guided ART. All prostate cancer patients treated with MR-guided ART on a 1.5T MR-linac were retrospectively reviewed. Consecutive RO-led (September 2019–November 2021) and RTT-led (April 2022–October 2023) cohorts were compared, excluding the actual transition period. Toxicities (CTCAE v5.0), dose–volume metrics from daily adapted plans, target volume variation, and biochemical recurrence-free survival (BRFS) were analyzed. A total of 166 patients were included (78 RO-led, 88 RTT-led; median follow-up 40 and 35 months). Dosimetric differences between the cohorts were statistically small (n = 2 vs. n = 0), likely reflecting higher baseline urinary dysfunction; no post-treatment differences persisted. Early biochemical outcomes were comparable, with 36-month BRFS of 93.5% (RO-led) and 95.0% (RTT-led). RTT-led MR-guided ART achieved comparable dosimetric quality and early biochemical outcomes to RO-led workflows with adverse advents that resolved in the long term. With structured training and a mature practice setting, RTT-led ART represents a scalable model to support future adaptive radiotherapy practice.
- Open Access
Outcomes following definitive treatment of malignant peripheral nerve sheath tumor are significantly worse for patients with neurofibromatosis type 1: A Canadian Sarcoma Research and Clinical Collaboration study
Background: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas with a 5‐year survival rate of approximately 50%, secondary to their metastatic potential and resistance to therapy. MPNSTs can arise sporadically, as a late toxicity from therapeutic radiotherapy, or in patients with neurofibromatosis type 1 (NF1). Prior studies have demonstrated conflicting results regarding the prognosis of NF1 associated MPNST compared to non‐NF1 associated MPNST (NF0). The authors hypothesized that NF1‐associated MPNSTs metastasize at a higher rate and are therefore associated with worse clinical outcomes. Methods: The authors collected data from 166 MPNST patients included in the Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) database. Of these, 54 had NF1. Patient demographics, overall survival (OS), cumulative incidence of progression or relapse (CIPR), and cumulative incidence of disease metastasis (CIDM) were assessed. Results: Patients with NF1 were younger ( p < .001) and had larger tumors at MPNST diagnosis ( p < .001). Two‐year OS was lower, and CIPR and CIDM were higher in NF1‐associated compared to NF0 MPNST. NF1 status, stage at diagnosis, tumor size, and positive surgical margins were adversely correlated to OS. Tumor location was an adverse prognostic factor for CIPR, and tumor size was the only adverse predictor for the CIDM in patients who underwent surgery. Conclusion: In summary, this study suggests that patients with NF1‐associated MPNSTs experience worse outcomes. NF1 associated MPNSTs were larger and arose in locations less amenable to negative (R0) resections. Among resectable tumors, CIDM, the primary driver of survival in patients initially diagnosed with localized disease, was correlated to tumor size but not NF1 status.
Open AccessOutcomes following definitive treatment of malignant peripheral nerve sheath tumor are significantly worse for patients with neurofibromatosis type 1: A Canadian Sarcoma Research and Clinical Collaboration study
Background: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas with a 5‐year survival rate of approximately 50%, secondary to their metastatic potential and resistance to therapy. MPNSTs can arise sporadically, as a late toxicity from therapeutic radiotherapy, or in patients with neurofibromatosis type 1 (NF1). Prior studies have demonstrated conflicting results regarding the prognosis of NF1 associated MPNST compared to non‐NF1 associated MPNST (NF0). The authors hypothesized that NF1‐associated MPNSTs metastasize at a higher rate and are therefore associated with worse clinical outcomes. Methods: The authors collected data from 166 MPNST patients included in the Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) database. Of these, 54 had NF1. Patient demographics, overall survival (OS), cumulative incidence of progression or relapse (CIPR), and cumulative incidence of disease metastasis (CIDM) were assessed. Results: Patients with NF1 were younger ( p < .001) and had larger tumors at MPNST diagnosis ( p < .001). Two‐year OS was lower, and CIPR and CIDM were higher in NF1‐associated compared to NF0 MPNST. NF1 status, stage at diagnosis, tumor size, and positive surgical margins were adversely correlated to OS. Tumor location was an adverse prognostic factor for CIPR, and tumor size was the only adverse predictor for the CIDM in patients who underwent surgery. Conclusion: In summary, this study suggests that patients with NF1‐associated MPNSTs experience worse outcomes. NF1 associated MPNSTs were larger and arose in locations less amenable to negative (R0) resections. Among resectable tumors, CIDM, the primary driver of survival in patients initially diagnosed with localized disease, was correlated to tumor size but not NF1 status.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (1) , e2500306
Pilot Health Care Provider Education Program for BRCA1 / 2 Genetic Testing, Counseling, and Management in Nigeria
PURPOSE: Breast cancer (BC) is a significant health challenge in Nigeria, exacerbated by early onset, advanced-stage diagnosis, and high prevalence of triple-negative tumors. Access to genetic testing and counseling is scarce, with minimal capacity for hereditary cancer services. Despite these barriers, there is strong interest in expanding care to include genetic testing and improve understanding of familial risk. The purpose of this study was to develop and assess the effectiveness of a BC genetics education program for Nigerian health care providers (HCPs). METHODS: A multidisciplinary international team developed a four-module hybrid education program combining asynchronous online learning and an in-person didactic session. Invitations were circulated to HCPs in tertiary hospitals across Nigeria. Knowledge improvement was assessed using standardized pre- and postmodule tests. RESULTS: Thirty-one physicians and nurses participated. All online modules had significant knowledge improvement, with the largest score increases in BRCA1 / 2 genetic counseling (mean change, 1.9 [95% CI, 1.3 to 2.5]; P < .001) and BRCA1 / 2 clinical management (mean change, 1.6 [95% CI, 1.2 to 2.1]; P < .001). The subsequent in-person workshop had additional, albeit smaller, module increases. Aggregated analysis showed a 23.0% increase in knowledge after the online training ( P < .001), with a further 10.1% gain after the in-person workshop ( P = .007). Overall knowledge improved from 45.0% at baseline to 87.0% post-training, representing a 43.0% absolute gain ( P < .001). CONCLUSION: This hybrid training program significantly improved provider knowledge of hereditary BC genetics in Nigeria and offers a scalable, culturally tailored model for expanding BC genetic services in low-resource settings. While promising, the modest sample size and limited follow-up warrant further evaluation and broader rollout to confirm long-term effectiveness.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (1) , e2500306
Pilot Health Care Provider Education Program for BRCA1 / 2 Genetic Testing, Counseling, and Management in Nigeria
PURPOSE: Breast cancer (BC) is a significant health challenge in Nigeria, exacerbated by early onset, advanced-stage diagnosis, and high prevalence of triple-negative tumors. Access to genetic testing and counseling is scarce, with minimal capacity for hereditary cancer services. Despite these barriers, there is strong interest in expanding care to include genetic testing and improve understanding of familial risk. The purpose of this study was to develop and assess the effectiveness of a BC genetics education program for Nigerian health care providers (HCPs). METHODS: A multidisciplinary international team developed a four-module hybrid education program combining asynchronous online learning and an in-person didactic session. Invitations were circulated to HCPs in tertiary hospitals across Nigeria. Knowledge improvement was assessed using standardized pre- and postmodule tests. RESULTS: Thirty-one physicians and nurses participated. All online modules had significant knowledge improvement, with the largest score increases in BRCA1 / 2 genetic counseling (mean change, 1.9 [95% CI, 1.3 to 2.5]; P < .001) and BRCA1 / 2 clinical management (mean change, 1.6 [95% CI, 1.2 to 2.1]; P < .001). The subsequent in-person workshop had additional, albeit smaller, module increases. Aggregated analysis showed a 23.0% increase in knowledge after the online training ( P < .001), with a further 10.1% gain after the in-person workshop ( P = .007). Overall knowledge improved from 45.0% at baseline to 87.0% post-training, representing a 43.0% absolute gain ( P < .001). CONCLUSION: This hybrid training program significantly improved provider knowledge of hereditary BC genetics in Nigeria and offers a scalable, culturally tailored model for expanding BC genetic services in low-resource settings. While promising, the modest sample size and limited follow-up warrant further evaluation and broader rollout to confirm long-term effectiveness.
- Open Access
- 25 October 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (11) , 1059
Surgical Resection Followed by Stereotactic Radiosurgery (S+SRS) Versus SRS Alone for Large Posterior Fossa Brain Metastases: A Comparative Analysis of Outcomes and Factors Guiding Treatment Modality Selection
Background/Objectives: Around 20% of cancer patients will develop brain metastases (BrMs), with 15–25% occurring in the posterior fossa (PF). Although the effectiveness of systemic therapies is increasing, surgery followed by stereotactic radiosurgery (S+SRS) versus definitive SRS remains the mainstay of treatment. Given the space restrictions within the PF, patients with BrMs in this location are at higher risk of brainstem compression, hydrocephalus, herniation, coma, and death. However, the criteria for treating large PF BrMs with S+SRS versus definitive SRS remains unclear. Methods: We reviewed a prospective registry database (2009 to 2020) and identified 64 patients with large PF BrMs (≥4 cc) treated with SRS or S+SRS. Clinical and radiological parameters were analyzed. The two endpoints were overall survival (OS) and local failure (LF). Results: Patients in the S+SRS group were more highly symptomatic than patients in the SRS group. Gait imbalance and intracranial pressure symptoms were 97% and 80%, and 47% and 35% for S+SRS and SRS, respectively. Radiologically, there were significant differences in the mean volume of the lesions [6.7 cm3 in SRS vs. 29.8 cm3 in the S+SRS cohort, (p < 0.001)]; compression of the fourth ventricle [47% in SRS vs. 96% in S+SRS cohort, (p < 0.001)]; and hydrocephalus [0% in SRS vs. 29% in S+SRS cohort, (p < 0.001)]. Patients treated with S+SRS had a higher Graded Prognostic Assessment (GPA). LF was 12 and 17 months for SRS and S+SRS, respectively. Moreover, the S+SRS group had improved OS (12 vs. 26 months, p = 0.001). Conclusions: A higher proportion of patients treated with S+SRS presented with hydrocephalus, fourth-ventricle compression, and larger lesion volumes. SRS-alone patients had a lower KPS, a lower GPA, and more brain metastases. S+SRS correlated with improved OS, suggesting that it should be seriously considered for patients with large PF-BrM.
- 25 October 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (11) , 1059
Open AccessSurgical Resection Followed by Stereotactic Radiosurgery (S+SRS) Versus SRS Alone for Large Posterior Fossa Brain Metastases: A Comparative Analysis of Outcomes and Factors Guiding Treatment Modality Selection
Background/Objectives: Around 20% of cancer patients will develop brain metastases (BrMs), with 15–25% occurring in the posterior fossa (PF). Although the effectiveness of systemic therapies is increasing, surgery followed by stereotactic radiosurgery (S+SRS) versus definitive SRS remains the mainstay of treatment. Given the space restrictions within the PF, patients with BrMs in this location are at higher risk of brainstem compression, hydrocephalus, herniation, coma, and death. However, the criteria for treating large PF BrMs with S+SRS versus definitive SRS remains unclear. Methods: We reviewed a prospective registry database (2009 to 2020) and identified 64 patients with large PF BrMs (≥4 cc) treated with SRS or S+SRS. Clinical and radiological parameters were analyzed. The two endpoints were overall survival (OS) and local failure (LF). Results: Patients in the S+SRS group were more highly symptomatic than patients in the SRS group. Gait imbalance and intracranial pressure symptoms were 97% and 80%, and 47% and 35% for S+SRS and SRS, respectively. Radiologically, there were significant differences in the mean volume of the lesions [6.7 cm3 in SRS vs. 29.8 cm3 in the S+SRS cohort, (p < 0.001)]; compression of the fourth ventricle [47% in SRS vs. 96% in S+SRS cohort, (p < 0.001)]; and hydrocephalus [0% in SRS vs. 29% in S+SRS cohort, (p < 0.001)]. Patients treated with S+SRS had a higher Graded Prognostic Assessment (GPA). LF was 12 and 17 months for SRS and S+SRS, respectively. Moreover, the S+SRS group had improved OS (12 vs. 26 months, p = 0.001). Conclusions: A higher proportion of patients treated with S+SRS presented with hydrocephalus, fourth-ventricle compression, and larger lesion volumes. SRS-alone patients had a lower KPS, a lower GPA, and more brain metastases. S+SRS correlated with improved OS, suggesting that it should be seriously considered for patients with large PF-BrM.
- 13 May 2024
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 169 (1) , 119-127
The incidence of brain metastases in breast cancer according to molecular subtype and stage: a 10-year single institution analysis
Background Breast cancer (BC) is the second most common etiology of brain metastases (BrM). We aimed to examine the incidence of BrM among all BC patients presenting to a large tertiary cancer centre over one decade. Methods We included all BC patients presenting consecutively between 2009 and 2019 and cross referenced that cohort to a radiotherapy database, identifying patients treated for BrM at any time following their initial presentation. Cumulative incidences (CI) of BrM diagnoses were calculated using death as a competing risk and compared using the Fine-Gray method. Overall survival was estimated using the Kaplan Meier method. Results We identified 12,995 unique patients. The CI of BrM in patients who initially presented with Stage 0–4 disease was 2.1%, 3.7%, 9.4%, 10.6%, and 28.7%, respectively at 10 years. For 8,951 patients with available molecular subtype data, 6,470 (72%), 961 (11%), 1,023 (11%), and 497 (6%) had hormone-receptor (HR)-positive/ERBB2-, HR-negative/ERBB2-, HR-positive/ERBB2 + , and HR-negative/ERBB2 + disease, respectively; the CI of BrM in each was 7.6%, 25.3%, 24.1%, and 26.6%, at 10 years following BC diagnosis, respectively. Median overall survival (OS) following BC diagnosis and BrM diagnosis was 28 years 95% CI [25, 32] and 10 months 95% CI [9, 12], respectively. Conclusions From a large, registry-based study, we observed that patients with ERBB2 + and triple negative BC have the highest incidence of BrM. Our data supports prospective surveillance brain MRI studies. Given advancements in BrM treatment, clinicians should have a low threshold for brain imaging in BC patients with high risk subtypes.
- 13 May 2024
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 169 (1) , 119-127
The incidence of brain metastases in breast cancer according to molecular subtype and stage: a 10-year single institution analysis
Background Breast cancer (BC) is the second most common etiology of brain metastases (BrM). We aimed to examine the incidence of BrM among all BC patients presenting to a large tertiary cancer centre over one decade. Methods We included all BC patients presenting consecutively between 2009 and 2019 and cross referenced that cohort to a radiotherapy database, identifying patients treated for BrM at any time following their initial presentation. Cumulative incidences (CI) of BrM diagnoses were calculated using death as a competing risk and compared using the Fine-Gray method. Overall survival was estimated using the Kaplan Meier method. Results We identified 12,995 unique patients. The CI of BrM in patients who initially presented with Stage 0–4 disease was 2.1%, 3.7%, 9.4%, 10.6%, and 28.7%, respectively at 10 years. For 8,951 patients with available molecular subtype data, 6,470 (72%), 961 (11%), 1,023 (11%), and 497 (6%) had hormone-receptor (HR)-positive/ERBB2-, HR-negative/ERBB2-, HR-positive/ERBB2 + , and HR-negative/ERBB2 + disease, respectively; the CI of BrM in each was 7.6%, 25.3%, 24.1%, and 26.6%, at 10 years following BC diagnosis, respectively. Median overall survival (OS) following BC diagnosis and BrM diagnosis was 28 years 95% CI [25, 32] and 10 months 95% CI [9, 12], respectively. Conclusions From a large, registry-based study, we observed that patients with ERBB2 + and triple negative BC have the highest incidence of BrM. Our data supports prospective surveillance brain MRI studies. Given advancements in BrM treatment, clinicians should have a low threshold for brain imaging in BC patients with high risk subtypes.
- 1 December 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 309 (3) , e231407
Association of PSMA PET-derived Parameters and Outcomes of Patients Treated for Oligorecurrent Prostate Cancer
Background Prostate-specific membrane antigen (PSMA) PET is useful in the early detection of oligorecurrent prostate cancer (PCa), but whether PSMA PET parameters can be used to identify patients who would benefit from metastasis-directed therapy (MDT) with radiation or surgery remains uncertain. Purpose To assess the association of PSMA PET parameters with outcomes of patients with oligorecurrent PCa after MDT. Materials and Methods In this retrospective analysis of a single-center phase II trial that enrolled patients with biochemical recurrence of PCa after maximal local therapy and with no evidence of disease at conventional imaging, patients underwent PSMA PET (between May 2017 and November 2021), and unveiled recurrences were treated with MDT. Maximum standardized uptake value (SUVmax) and mean standardized uptake value (SUVmean) and PSMA tumor volume derived using thresholds of 2.5 (SUVmean2.5) and 41% (SUVmean41%), respectively, were recorded for sites of recurrence on PSMA PET scans, and a molecular imaging PSMA score was assigned. These parameters were also corrected for smooth filter and partial volume effects, and the PSMA score was reassigned. Cox proportional hazards models were used to evaluate the relationship between PSMA PET parameters and outcomes. Results A total of 74 men (mean age, 68.3 years ± 6.6 [SD]) with biochemical recurrence of PCa were included. PSMA PET revealed 145 lesions in the entire cohort, of which 125 (86%) were metastatic lymph nodes. Application of the correction factor changed the PSMA score in 88 of 145 lesions (61%). Mean SUVmax, SUVmean2.5, and SUVmean41% were associated with lower risk of biochemical progression (hazard ratio [HR] range, 0.77-0.95; 95% CI: 0.61, 1.00; P = .03 to P = .04). For corrected parameters, mean SUVmax, mean SUVmean2.5, mean SUVmean41%, mean PSMA score, maximum SUVmean2.5, maximum SUVmean41%, and maximum PSMA score were associated with a lower risk of biochemical progression (HR, 0.61-0.98; 95% CI: 0.39, 1.00; P = .01 to P = .04). Conclusion Measured and corrected PSMA PET parameters were associated with biochemical progression in men with oligorecurrent PCa treated with MDT. Clinical trial registration no. NCT03160794 © RSNA, 2023 See also the editorial by Civelek in this issue.
- 1 December 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 309 (3) , e231407
Association of PSMA PET-derived Parameters and Outcomes of Patients Treated for Oligorecurrent Prostate Cancer
Background Prostate-specific membrane antigen (PSMA) PET is useful in the early detection of oligorecurrent prostate cancer (PCa), but whether PSMA PET parameters can be used to identify patients who would benefit from metastasis-directed therapy (MDT) with radiation or surgery remains uncertain. Purpose To assess the association of PSMA PET parameters with outcomes of patients with oligorecurrent PCa after MDT. Materials and Methods In this retrospective analysis of a single-center phase II trial that enrolled patients with biochemical recurrence of PCa after maximal local therapy and with no evidence of disease at conventional imaging, patients underwent PSMA PET (between May 2017 and November 2021), and unveiled recurrences were treated with MDT. Maximum standardized uptake value (SUVmax) and mean standardized uptake value (SUVmean) and PSMA tumor volume derived using thresholds of 2.5 (SUVmean2.5) and 41% (SUVmean41%), respectively, were recorded for sites of recurrence on PSMA PET scans, and a molecular imaging PSMA score was assigned. These parameters were also corrected for smooth filter and partial volume effects, and the PSMA score was reassigned. Cox proportional hazards models were used to evaluate the relationship between PSMA PET parameters and outcomes. Results A total of 74 men (mean age, 68.3 years ± 6.6 [SD]) with biochemical recurrence of PCa were included. PSMA PET revealed 145 lesions in the entire cohort, of which 125 (86%) were metastatic lymph nodes. Application of the correction factor changed the PSMA score in 88 of 145 lesions (61%). Mean SUVmax, SUVmean2.5, and SUVmean41% were associated with lower risk of biochemical progression (hazard ratio [HR] range, 0.77-0.95; 95% CI: 0.61, 1.00; P = .03 to P = .04). For corrected parameters, mean SUVmax, mean SUVmean2.5, mean SUVmean41%, mean PSMA score, maximum SUVmean2.5, maximum SUVmean41%, and maximum PSMA score were associated with a lower risk of biochemical progression (HR, 0.61-0.98; 95% CI: 0.39, 1.00; P = .01 to P = .04). Conclusion Measured and corrected PSMA PET parameters were associated with biochemical progression in men with oligorecurrent PCa treated with MDT. Clinical trial registration no. NCT03160794 © RSNA, 2023 See also the editorial by Civelek in this issue.
- 28 November 2023
- Published by The R Foundation
BiostatsUHNplus: Nested Data Summary, Adverse Events and REDCap
- 28 November 2023
- Published by The R Foundation
BiostatsUHNplus: Nested Data Summary, Adverse Events and REDCap
- Open Access
- 25 July 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 42, 100663
A total inverse planning paradigm: Prospective clinical trial evaluating the performance of a novel MR-based 3D-printed head immobilization device
- 25 July 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 42, 100663
Open AccessA total inverse planning paradigm: Prospective clinical trial evaluating the performance of a novel MR-based 3D-printed head immobilization device